Overall impact
B (61)

Commentary

IMARA is a strong overall performer. With a 'B' rating of 60.6 for overall impact (64th percentile compared to all companies), IMARA ranks 401st out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 397 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 181 others. On top material causes for IMARA's industry (Pharmaceuticals & Biotech), IMARA performs well in Access to Affordable Healthcare (84.9 score), Disease Eradication (96.4) and Improved Mental Health (95.3) and performs poorly in Reduced Use of tobacco (38.3 score), Humane Treatment of Animals (18.3), Reduced Green House Gas Emissions (34.1) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause IMRA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2016
Employees
6
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ma, United States
Share classes
IMRA
Description
IMARA Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapeutics to treat patients suffering from serious diseases. The company was incorporated in 2016 and is based in Brookline, Massachusetts.
Material causes
Ethos considers the following causes material for IMARA, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.